Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14101 - 14125 of 15152 in total
Investigational
Vet approved
Experimental
KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity (involuntary abnormal contraction of the bladder). The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels...
Investigational
Matched Description: … a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and ... bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and
SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Investigational
Matched Description: … gel, has been combined with a widely available light source for permanent removal of unwanted hair and
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
Investigational
Matched Description: … anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and
SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).
Investigational
Matched Description: … investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and
Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and
AZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).
Investigational
Matched Description: … trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and
GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
Matched Description: … GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and
Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
Investigational
Matched Description: … is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and
Cardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
Investigational
Matched Description: … investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and
SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.
Investigational
Matched Description: … the most promising compound from a new series of renin inhibitors for the treatment of hypertension and
XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II.
Investigational
Matched Description: … monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and
PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and Chronic Obstructive Pulmonary Disease (COPD).
Investigational
Matched Description: … 03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and
Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Experimental
Matched Description: … It is an antagonist at D1 and D2 dopamine receptors. …
Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).
Investigational
Matched Description: … Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and
ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
Investigational
Matched Description: … ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And
AZD8529 is under investigation in clinical trial NCT00921804 (Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients).
Investigational
Matched Description: … AZD8529 is under investigation in clinical trial NCT00921804 (Study to Assess the Efficacy, Safety, and
Landipirdine is under investigation in clinical trial NCT02258152 (SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)).
Investigational
Matched Description: … under investigation in clinical trial NCT02258152 (SYN120 Study to Evaluate Its Safety, Tolerability and
Levotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).
Investigational
Matched Description: … NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and
Displaying drugs 14101 - 14125 of 15152 in total